JP2016526875A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526875A5
JP2016526875A5 JP2016514143A JP2016514143A JP2016526875A5 JP 2016526875 A5 JP2016526875 A5 JP 2016526875A5 JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016526875 A5 JP2016526875 A5 JP 2016526875A5
Authority
JP
Japan
Prior art keywords
seq
variant
subject
variants
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016514143A
Other languages
English (en)
Japanese (ja)
Other versions
JP6482533B2 (ja
JP2016526875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/038468 external-priority patent/WO2014186750A2/en
Publication of JP2016526875A publication Critical patent/JP2016526875A/ja
Publication of JP2016526875A5 publication Critical patent/JP2016526875A5/ja
Application granted granted Critical
Publication of JP6482533B2 publication Critical patent/JP6482533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016514143A 2013-05-17 2014-05-16 クローン病に関連するtnfsf15及びdcr3の変異体 Active JP6482533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17
PCT/US2014/038468 WO2014186750A2 (en) 2013-05-17 2014-05-16 Variants of tnfsf15 and dcr3 associated with crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018124311A Division JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するtnfsf15及びdcr3の変異体

Publications (3)

Publication Number Publication Date
JP2016526875A JP2016526875A (ja) 2016-09-08
JP2016526875A5 true JP2016526875A5 (cg-RX-API-DMAC7.html) 2017-06-15
JP6482533B2 JP6482533B2 (ja) 2019-03-13

Family

ID=51899024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するtnfsf15及びdcr3の変異体
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するtnfsf15及びdcr3の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するtnfsf15及びdcr3の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するtnfsf15及びdcr3の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するtnfsf15及びdcr3の変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するtnfsf15及びdcr3の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するtnfsf15及びdcr3の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するtnfsf15及びdcr3の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するtnfsf15及びdcr3の変異体

Country Status (7)

Country Link
US (4) US20160090629A1 (cg-RX-API-DMAC7.html)
EP (3) EP3498867B1 (cg-RX-API-DMAC7.html)
JP (5) JP6482533B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230093538A (cg-RX-API-DMAC7.html)
CN (1) CN105358713B (cg-RX-API-DMAC7.html)
ES (1) ES2894963T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014186750A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
JP2014531210A (ja) 2011-09-30 2014-11-27 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド TL1aに対する抗体およびその使用
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
EP3498867B1 (en) 2013-05-17 2021-09-29 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
EP3337465B1 (en) 2015-08-21 2021-11-24 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3458466B1 (en) * 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
EP3846851A4 (en) * 2018-09-07 2022-09-21 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISORDERS OF THE LYMPHATIC SYSTEM
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
BR112022004590A2 (pt) * 2019-09-13 2022-06-14 Kyowa Kirin Co Ltd Variante dcr3
PH12023500011A1 (en) * 2020-11-13 2024-03-11 Cedars Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
SI2257643T1 (sl) 2008-02-19 2018-12-31 The Children's Hospital Of Philadelphia Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
AU2010236568B2 (en) * 2009-04-14 2015-08-27 Société des Produits Nestlé S.A. Inflammatory bowel disease prognostics
EP2630495B1 (en) 2010-10-18 2017-02-08 Nestec S.A. Methods for determining anti-drug antibody isotypes
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
WO2012161856A1 (en) * 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
CA2841416A1 (en) 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
JP2015502740A (ja) 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
EP3498867B1 (en) 2013-05-17 2021-09-29 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Similar Documents

Publication Publication Date Title
JP2016526875A5 (cg-RX-API-DMAC7.html)
Boyapati et al. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications
JP2020127437A5 (cg-RX-API-DMAC7.html)
JP2014515599A5 (cg-RX-API-DMAC7.html)
JP2017522908A5 (cg-RX-API-DMAC7.html)
JP2018148931A5 (cg-RX-API-DMAC7.html)
Hsu et al. Avian hepatitis E virus in chickens, Taiwan, 2013
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
JP2015511121A5 (cg-RX-API-DMAC7.html)
Dacheux et al. Dual combined real-time reverse transcription polymerase chain reaction assay for the diagnosis of lyssavirus infection
JP2017032581A5 (cg-RX-API-DMAC7.html)
WO2013022995A3 (en) Biomarker compositions and methods
WO2013134786A3 (en) Biomarker compositions and methods
Allen et al. Emergence of the GII-4 Norovirus Sydney2012 strain in England, winter 2012–2013
Anh et al. The prevalence and genetic diversity of group A rotaviruses on pig farms in the Mekong Delta region of Vietnam
WO2012174282A3 (en) Biomarker compositions and methods
JP2021503610A5 (cg-RX-API-DMAC7.html)
JP2015523569A5 (cg-RX-API-DMAC7.html)
WO2019051257A3 (en) Methods for treating hepatitis b infections
WO2014186750A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
Kaneko et al. Identification of vaccine-derived rotavirus strains in children with acute gastroenteritis in Japan, 2012-2015
JP2013063090A5 (cg-RX-API-DMAC7.html)
WO2018202931A3 (es) Método de diagnóstico de placas ateroscleróticas inestables
Srivastava et al. New record of Papaya leaf curl virus and Ageratum leaf curl beta satellite associated with yellow vein disease of aster in India
JP2006311860A5 (cg-RX-API-DMAC7.html)